Rallis India Q1 FY27 Earnings Call — Analysis (NSE: RALLIS)

Rallis India delivers 7% revenue growth and 31% PAT jump in Q1FY27 despite weak monsoon, war-led cost pressures and cotton acreage decline; domestic Crop Care surges 19%.

27 Jul 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Revenue ₹1,022 Cr ( +7% YoY ) . New guidance — FY27 cotton seed revenue flat / not much growth . New story: Domestic formulation volume surge .

Results

Revenue ₹1,022 Cr +7% YoY; EBITDA ₹184 Cr +23% YoY; PAT ₹125 Cr +31% YoY. Domestic Crop Care grew 19% (B2C volume +15%) while exports de-grew 28% on weak demand and Chinese competition.

Financial highlights

Guidance

Management cited consensus estimates for Indian agrochemicals industry growth of 6-8% and seeds mid-to-high single digits (ex-cotton) in FY27; company aims to drive volumes and capture market share.

What management committed to

• Indian agrochemicals industry is expected to grow 6-8% in FY27, while seeds likely grow mid-to-high single digits (excluding cotton, which will see a significant decline). — 6-8% for agrochemicals, mid-to-high single digits for seeds ex-cotton, FY27
• [Rallis] wants to be a consistent company which delivers 15% plus EBITDA margin even in a bad year. — 15% plus, long-term
• [Rallis] will launch 3 to 4 new catalogue products in exports over the next 3 years. — 3 to 4 products, FY29
• [Rallis] cotton seed revenue will not grow much in FY27, likely remaining flat. — flat / not much growth, FY27
• Seeds from crops other than cotton (rice, maize, millet, mustard) will grow significantly over last year. — grow significantly, FY27
• Biologicals business should do significantly better than last year. — significantly better, FY27

Key themes

El Niño, war cost pressure, domestic strength, cotton drag

How the narrative shifted

• El Niño and weak monsoon: Management frames delayed monsoon and below-normal rainfall as the dominant headwind for Kharif sowing, causing shifts in crop mix and deferring agrochemical offtake, but expects catch-up sowing and no structural shortage.
• Middle East war cost pass-through: Management attributes elevated feedstock, energy, and freight costs to the West Asia conflict, compressing margins; price increases only partially offset costs, and the situation remains fragile with recent escalation.
• Domestic formulation volume surge: Domestic B2C Crop Care delivered 19% growth with 15% volume growth, driven by aggressive preplacement, digital demand generation, and market share gains; management highlights this as the key growth engine.
• Exports under Chinese pricing pressure: Exports degrew sharply due to lower European demand and Chinese price competition, especially in acephate (raw material dependency). Management acknowledges competitiveness challenges but remains optimistic on other molecules and CSM contracts.
• Seeds diversification away from cotton: With cotton acreage declining due to illegal HTBT cotton and rain deficits, the company is pivoting to five strategic crops—rice, maize, millet, mustard—and launching new hybrids to drive growth, expecting significant growth in non-cotton seeds.
• Working capital and channel inventory stress: Channel cash crunch from fertilizer stocking caused delayed crop protection offtake and elevated inventory; working capital days increased 15-20 days YoY, though collection cycles remain smooth and cash balance healthy.
• Digital and R&D driven go-to-market: Management highlights digital platforms (Anubandh Edge, Sampark+) and sharper R&D focus (only 5 crops, no GM or vegetable seeds) as levers for demand generation and long-term competitiveness.

Operational commentary

• Domestic B2C Crop Care volume growth of 15% driven by aggressive preplacement, liquidation efforts, and digital demand generation.
• Exports de-grew 28% (volumes -35%) due to lower pendimethalin demand in Europe, competitive Chinese pricing on acephate, Pendi CS, Hexaconazole, and logistical disruptions.
• CSM revenue rebounded 191% on recovery in PEKK sales; first shipment to a new U.S. customer well-received.
• Seeds business focused on five strategic crops—Cotton, Maize, Millet, Mustard, Rice—with new hybrid launches (2 cotton hybrids, herbicide-tolerant direct-seeded rice, short-duration Bajra) to offset cotton acreage decline.
• Digital ecosystem expansion: Anubandh Edge retailer registrations crossed 56,000; Sampark+ capturing farmer-level demand signals; Idea2Impact open innovation platform received ~40 applications, 2 in pilot.
• Formulation capacity utilization increased YoY in Q1FY27.
• Working capital days increased 15-20 days YoY due to fertilizer-linked cash crunch in the channel; inventory elevated but collection cycles smooth.
• Management proactively reduced cotton seed production acreage to manage inventory; expects seed industry as a whole to be in surplus for the coming season.

Analyst Q&A

• Q. How are you seeing product-wise demand and pricing in exports given Chinese competition?

  Exports challenging unless you have a branded business. CSM is fine because of contracts. For catalogue products we must remain competitive; acephate is problematic because raw material must come from China and they also export to the same markets. Other products like pendimethalin, metribuzin, hexaconazole, metalaxyl we remain competitive.

• Q. Given lower cotton acreage and our portfolio skew, what are domestic crop protection growth expectations?

  Cotton takes many sprays; last year too much rain prevented spraying. This year intermittent rain may still allow sprays. Also we are shifting focus to rice, maize, millet where we launched new products. Cotton will remain important and should recover; not very pessimistic at this point.

• Q. What is the impact of delayed monsoon on seed production for next year?

  Nobody can predict. Majority of seed production happens in October; cotton production already in field; we proactively reduced cotton seed production acreage. Industry is sitting on surplus this year. If there is significant failure of cotton seed production in current season it could become a challenge, but we'll know by October-December.

• Q. Could you explain the INR 35 Cr provision reversal in employee cost and the sharp increase in other expenses?

  INR 11 Cr is recurring annual performance incentive reversal in Q1. The remaining INR 24 Cr is a one-time restructuring and retiral correction, unlikely to repeat. Adjusted employee cost increase is ~12% YoY, in line with normal inflation.

View source

Research and educational content only. Not investment advice.